Q3 2024 Altimmune Inc Earnings Call Transcript

Nov 12, 2024 / 01:30 PM GMT

Release Date Price: €8.91 (+32.59%)

Transcript 10-Q8-K

Key Points

Positve

Altimmune Inc (ALT) has fully enrolled its Phase 2B impact trial for PTI IN MS, with top-line efficacy data expected in Q2 2025.
The company achieved alignment with the FDA on a comprehensive Phase 3 registration program for its obesity program, indicating a clear regulatory path forward.
Altimmune Inc (ALT) plans to expand its R&D investments into three additional indications, leveraging the enhanced glucagon activity of its product.
The company has a strong cash position, with $139.4 million in cash, cash equivalents, and short-term investments, projected to fund operations into the first half of 2026.
Altimmune Inc (ALT) has received positive feedback from the FDA regarding the safety profile of its product, with no safety signals identified in its trials.

Negative

The company's net loss for Q3 2024 was $22.8 million, an increase from the $20.7 million loss in the same period of 2023.
Research and development expenses increased to $19.8 million in Q3 2024 from $18.4 million in Q3 2023, indicating rising costs.
General and administrative expenses also rose to $5 million in Q3 2024 from $4.5 million in Q3 2023, primarily due to increased professional services costs.
The company is still seeking strategic partnerships, indicating potential challenges in securing collaborations for its obesity program.
There is uncertainty regarding the timing and sequencing of the Phase 3 trials, which could impact the overall development timeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALT.OQ - Altimmune Inc
Q3 2024 Altimmune Inc Earnings Call
Nov 12, 2024 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day. Ladies and gentlemen and welcome to Altimmune Inc third quarter, 2024 financial results conference call at this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question. Please press star 11 again as a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, lee Roth of Burns mcclellan Investor Relations advisor to Altimmune, Lee. You may begin.

------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.